Foghorn Therapeutics Inc. Stock Price, News & Analysis

Foghorn Therapeutics (Nasdaq: FHTX) announced a full clinical hold by the FDA on the Phase 1 study of its drug FHD-286 for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). This decision arose from reports of additional suspected fatal differentiation syndrome cases linked to FHD-286. Meanwhile, the study for metastatic uveal melanoma is proceeding as planned, with data expected in early 2023. Foghorn remains committed to addressing FDA concerns to lift the hold promptly.

Foghorn Therapeutics (Nasdaq: FHTX) announced the election of B. Lynne Parshall to its Board as the Chair of the Audit Committee. With nearly 30 years in biotechnology and experience at Ionis Pharmaceuticals, her leadership is expected to bolster Foghorn's growth. CEO Adrian Gottschalk emphasized that her track record in therapy development will be pivotal as the company works towards its vision of a fully-integrated biotech. Parshall will play a crucial role in advancing key clinical programs, including FHD-286 and FHD-609.

Foghorn Therapeutics (FHTX) provided a corporate and financial update for Q2 2022. The Phase 1 study of FHD-286 in metastatic uveal melanoma is progressing, while a partial clinical hold by the FDA affects its use in AML and MDS. Initial clinical data for FHD-609 in synovial sarcoma is expected in 2023. The company achieved a research milestone under its Merck collaboration, triggering a $5 million payment. As of June 30, 2022, Foghorn reported $394.7 million in cash and equivalents, indicating strong financial health.

Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in key investor conferences throughout August 2022, focusing on oncology and the innovative Gene Traffic Control platform. Key events include virtual meetings on August 8 and a panel discussion at the 13th Annual Wedbush PacGrow Healthcare Conference on August 9 at 10:20 a.m. ET. Foghorn is advancing a pipeline of drug candidates that target genetically determined dependencies, with two currently in clinical studies. A webcast of the panel will be available for up to 90 days after the event.

Foghorn Therapeutics (Nasdaq: FHTX) has announced its participation in three upcoming investor conferences. The focus is on its Gene Traffic Control® Platform, which aims to innovate oncology treatments. Key events include:

• Cowen's 3rd Annual Oncology Innovation Summit on June 2 at 10:30 a.m. ET.
• Jefferies Healthcare Conference on June 8 at 1:30 p.m. ET.
• Goldman Sachs 43rd Annual Global Healthcare Conference on June 13 at 3:20 p.m. PT.

Webcasts will be available via the company's website post-event.

Foghorn Therapeutics (Nasdaq: FHTX) announced that the FDA has placed a partial clinical hold on its Phase 1 study of FHD-286 in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), following a report of a death linked to potential differentiation syndrome. While existing patients can continue treatment, new patient enrollment is halted until the issue is resolved. This hold does not affect the ongoing FHD-286 study for metastatic uveal melanoma. The company is suspending guidance on data release timing for the AML/MDS study.

Foghorn Therapeutics (FHTX) continues to advance its pipeline with three phase 1 studies targeting the chromatin regulatory system. Initial clinical data for FHD-286 is anticipated in H2 2022, focusing on cancers such as AML and uveal melanoma, while FHD-609 aims for data in 2023. Recent preclinical findings at AACR highlight FHD-286's anti-tumor activity. The company reported a strong balance sheet with $424.7 million in cash as of March 31, 2022, supporting ongoing development efforts.

Foghorn Therapeutics (FHTX) presented promising preclinical data on its dual inhibitor, FHD-286, at the 2022 AACR Annual Meeting. Targeting the chromatin regulatory system, FHD-286 shows potential in treating cancer, particularly acute myeloid leukemia (AML) and metastatic uveal melanoma. Key findings include significant anti-tumor activity in AML models and favorable combination effects with existing therapies. The data support ongoing Phase 1 trials and underscore FHTX's innovative Gene Traffic Control platform aimed at transforming cancer treatment.

Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in the AACR Annual Meeting from April 8-13, 2022, in New Orleans. The company will present preclinical data for FHD-286, a novel BAF inhibitor targeting cancers like acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS), and metastatic uveal melanoma (UM). The oral presentation is set for April 11, showcasing the pharmacological profile and anti-tumor properties of FHD-286. The late-breaking poster on April 13 will address the modulation of SPI1 transcriptional programs related to AML.